Catalent Pharma Solutions and CEVEC Pharmaceuticals have entered a joint commercial cell line development service for pharma and biotech customers worldwide. The offering combines CEVEC’s human cell line, CAP-Technology, with Catalent’s GPEx (Gene Product Expression) Technology to generate high expressing stable human cell lines in a shorter timeframe than traditional methods. “We are very pleased to be working with Catalent and their truly unique technology to generate stable lines,” said Dr. ...